痴呆老年人临终前一年使用可疑获益药物的研究
瑞典全国注册队列研究纳入120,067例≥75岁痴呆死亡者,分析临终前12个月可疑获益药物使用情况。结果显示至少使用1种可疑获益药物的比例从死亡前12个月的38.6%降至临终前1个月的34.7%(趋势P<.001),其中74.8%在12个月前使用者持续暴露至临终前1个月。机构居住与临终前1个月使用≥1种可疑获益药物的可能性降低15%独立相关(OR 0.85,95%CI 0.88-0.83)。
要点
- 痴呆老年人临终前一年可疑获益药物使用比例从38.6%降至34.7%(P<.001)。
- 12个月前使用可疑获益药物者中74.8%持续至临终前1个月。
- 机构居住者临终前1个月使用可疑获益药物的OR为0.85(95%CI 0.88-0.83)。
核心结论
- 痴呆老年人临终前一年可疑获益药物使用比例仅小幅下降,多数早期使用者持续暴露至临终前。
研究设计与样本
- 基于瑞典全国注册的纵向队列研究,纳入2007至2013年死亡的所有≥75岁痴呆老年人(n=120,067),利用瑞典处方药注册数据计算临终前12个月每月可疑获益药物暴露。
主要发现
- 至少使用1种可疑获益药物的比例从死亡前12个月的38.6%降至临终前1个月的34.7%(趋势P<.001)。
- 12个月前使用至少1种可疑获益药物者中,74.8%持续暴露至临终前1个月。
- 机构居住与临终前1个月使用≥1种可疑获益药物的可能性降低15%独立相关(OR 0.85,95%CI 0.88-0.83)。
- 抗痴呆药物占可疑获益药物总数的五分之一。
- 临终前1个月降脂药使用率为8.3%(社区居住者10.2%,机构居住者6.6%,P<.001)。
关键数值与推荐
- 至少使用1种可疑获益药物的比例:死亡前12个月38.6%,临终前1个月34.7%(趋势P<.001)。
- 12个月前使用至少1种可疑获益药物者中持续暴露至临终前1个月的比例为74.8%。
- 机构居住与临终前1个月使用≥1种可疑获益药物的OR为0.85(95%CI 0.88-0.83)。
- 抗痴呆药物占可疑获益药物总数的五分之一。
- 临终前1个月降脂药使用率:总体8.3%,社区居住者10.2%,机构居住者6.6%(P<.001)。
临床怎么用
- 对晚期痴呆老年人应使用可靠工具评估并减少可疑获益药物的负担,尤其在临终前阶段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the prevalence and factors associated with the use of medications of questionable benefit throughout the final year of life of older adults who died with dementia. DESIGN: Register-based, longitudinal cohort study. SETTING: Entire Sweden. PARTICIPANTS: All older adults (≥75 years) who died with dementia between 2007 and 2013 (n = 120,067). MEASUREMENTS: Exposure to medications of questionable benefit was calculated for each of the last 12 months before death, based on longitudinal data from the Swedish Prescribed Drug Register. RESULTS: The proportion of older adults with dementia who received at least 1 medication of questionable benefit decreased from 38.6% 12 months before death to 34.7% during the final month before death (P < .001 for trend). Among older adults with dementia who used at least 1 medication of questionable benefit 12 months before death, 74.8% remained exposed until their last month of life. Living in an institution was independently associated with a 15% reduction of the likelihood to receive ≥1 medication of questionable benefit during the last month before death (odds ratio 0.85, 95% confidence interval 0.88-0.83). Antidementia drugs accounted for one-fifth of the total number of medications of questionable benefit. Lipid-lowering agents were used by 8.3% of individuals during their final month of life (10.2% of community-dwellers and 6.6% of institutionalized people, P < .001). CONCLUSION: Clinicians caring for older adults with advanced dementia should be provided with reliable tools to help them reduce the burden of medications of questionable benefit near the end of life.
引用
- Morin L, Vetrano DL, Grande G, et al. Use of Medications of Questionable Benefit During the Last Year of Life of Older Adults With Dementia. J Am Med Dir Assoc. 2017. PMID: 28431913. doi:10.1016/j.jamda.2017.02.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。